多病共存与药物治疗模式:一项全人群横断面研究
本研究基于瑞典斯德哥尔摩地区2017年全人群数据库(N=2 323 667),分析多病共存患者的人口学特征、处方药使用、死亡风险及疾病非随机关联。结果显示21.6%存在多病共存,24.1%存在多重用药,识别出七个临床特征不同的多病共存聚类,提示指南应关注疾病聚集模式以管理复杂性。
要点
- 全人群中21.6%有多病共存,24.1%有多重用药。
- 随多病共存增加,处方药数、精神与躯体共病及1年死亡率均上升。
- 识别出七个多病共存聚类,最大聚类以心理健康问题为主且较年轻。
核心结论
- 慢性病患者常表现为临床复杂性,兼具一致性与不一致性共病及多重用药。
- 针对疾病聚集模式的临床指南可能是管理复杂性的一种策略。
研究设计与样本
- 横断面描述性全人群队列研究,数据来自瑞典VAL数据库(N=2 323 667),涵盖2017年所有初级和专科门诊、住院及处方记录。
- 分析按性别分层,使用聚类分析检查疾病间非随机关联。
主要发现
- 21.6%有多病共存(两种及以上慢性病),24.1%有多重用药(超过五种处方药)。
- 随着多病共存增加,处方药数量、精神与躯体共病共存及1年死亡率均增加。
- 识别出七个临床特征不同的多病共存聚类。
- 最小聚类(7%个体)以心血管疾病突出,1年死亡率最高,多病共存和多重用药水平高,年龄更大。
- 最大聚类(27%个体)较年轻且异质,以心理健康问题为主。
临床怎么用
- 全科医生应关注多病共存患者的精神与躯体共病及多重用药,评估1年死亡风险。
- 可参考疾病聚类模式识别高风险患者,如心血管疾病突出且年龄较大的小聚类。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment of multimorbid patients can be improved. Development of patient-centred care of high-quality requires context-bound understanding of the multimorbid population's patterns of demographics, co-morbidities and medication use. OBJECTIVE: The aim of this study was to identify patterns of multimorbidity in the total population of Region Stockholm, Sweden, by exploring demographics, claimed prescription drugs, risk of mortality and non-random association of conditions. METHODS: In this cross-sectional descriptive population-based cohort study, we extracted data from the Swedish VAL database (N = 2 323 667) including all consultations in primary and specialized outpatient care, all inpatient care and all prescriptions claimed during 2017. We report number of chronic conditions and claimed prescription drugs, physical and mental co-morbidity, and 1-year mortality. We stratified the analyses by sex. We examined non-random associations between diseases using cluster analysis. RESULTS: In total, 21.6% had multimorbidity (two or more chronic conditions) and 24.1% had polypharmacy (more than five claimed prescription drugs). Number of claimed drugs, co-occurrence of mental and physical conditions, and 1-year mortality increased as multimorbidity increased. We identified seven multimorbidity clusters with clinically distinct characteristics. The smallest cluster (7% of individuals) had prominent cardiovascular disease, the highest 1-year mortality rate, high levels of multimorbidity and polypharmacy, and was much older. The largest cluster (27% of individuals) was younger and heterogenous, with primarily mental health problems. CONCLUSIONS: Individuals with chronic conditions often show clinical complexity with both concordant and discordant conditions and polypharmacy. This study indicates that clinical guidelines addressing clustering of conditions may be one strategy for managing complexity.
引用
- Forslund T, Carlsson AC, Ljunggren G, et al. Patterns of multimorbidity and pharmacotherapy: a total population cross-sectional study. Fam Pract. 2021. PMID: 32766818. doi:10.1093/fampra/cmaa056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。